Bristol immunotherapy shows promise in lung cancer trial
October 30, 2014 at 09:00 AM EDT
Oct 30 (Reuters) - Treatment of advanced squamous cell non-small cell lung cancer (NSCLC) with Bristol-Myers Squibb Co's experimental immunotherapy nivolumab led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data being presented at a medical meeting.
